SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): April 13, 2004
GENOME THERAPEUTICS CORP.
(Exact name of registrant as specified in its charter)
| Massachusetts | 0-10824 | 04-2297484 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
100 Beaver Street
Waltham, Massachusetts 02453
(Address of principal executive offices, including zip code)
(781) 398-2300
(Registrant’s telephone number, including area code)
ITEM 5. OTHER EVENTS
On April 13, 2004, Genome Therapeutics Corp. issued a press release announcing that its shareholders had approved an amendment to the Company’s Articles of Incorporation to change its name to “Oscient Pharmaceuticals Corporation.” A copy of the press release is attached hereto as Exhibit 99.1.
Item 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
| 99.1 | Press Release issued by Genome Therapeutics Corp. on April 13, 2004. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GENOME THERAPEUTICS CORP. | ||
| By: |
/s/ Stephen Cohen | |
| Name: |
Stephen Cohen | |
| Title: |
Senior Vice President and Chief Financial Officer | |
Date: April 13, 2004
3
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 99.1 | Press Release issued by Genome Therapeutics Corp. on April 13, 2004. |
4